Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of OP-2024 in advanced Parkinson's disease
jRCT2021230019Phase 2Completed
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Nov 2023
- Countries
- 1
01
Overview
Phase 2 trial of OP-2024-C in Parkinson's disease (PD) (2 arms), sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Safety. Started Nov 2023; status: completed.
02
Drugs
OP-2024-C
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2021230019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230019.